uMI Panvivo

The uMI Panvivo is an advanced PET/CT imaging system designed to provide comprehensive anatomical and functional information through the synergistic use of a 160-slice CT and a LYSO-based PET with a 295mm axial field of view. It employs sophisticated image reconstruction technologies, including HYPER Iterative and AI-enhanced AIEFOV, to improve image quality and diagnostic capabilities across oncology, neurology, and inflammation/infection imaging, as well as for low-dose lung cancer screening and radiotherapy planning.

The uMI Panvivo is an integrated Positron Emission Tomography/Computed Tomography (PET/CT) system designed to deliver both functional and anatomical images. Its PET component visualizes the distribution of specific radiopharmaceuticals to assess metabolic and molecular physiologic functions, while the CT component provides detailed diagnostic tomographic anatomical information and photon attenuation data for the scanned region. The system, comprising the PET and CT units, a patient table, and a control/reconstruction system, allows for separate or combined scans, facilitating a comprehensive evaluation of various body parts. This system is intended for a wide range of clinical applications, including the detection, localization, diagnosis, staging, monitoring, and follow-up of abnormalities such as tumors, inflammation, and infections, particularly in oncology, neurology, and infection/inflammation studies. Key technological features include a 295 mm axial field of view (AFOV) PET system with LYSO detectors, a 160-slice CT, a 700 mm patient bore, and a 250 kg table capacity. It incorporates advanced imaging technologies like HYPER Iterative reconstruction to manage image noise and AIEFOV, an AI-driven algorithm using deep learning and extrapolation to extend the field of view and enhance CT value accuracy without compromising scan field of view data. Additionally, the CT system supports low-dose lung cancer screening protocols and can aid in radiotherapy treatment planning and interventional radiology procedures.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AIEFOV algorithm's deep learning component specifically enhance processing efficiency and CT value accuracy in the extended field of view compared to traditional extrapolation methods?; What is the quantitative impact of the HYPER Iterative reconstruction algorithm on image noise levels and the number of permissible iterations for different types of PET scans (e.g., oncology vs. neurology)?; Are there specific radiopharmaceuticals for which the uMI Panvivo's 295 mm axial FOV and LYSO detector offer demonstrably superior performance in terms of sensitivity or spatial resolution compared to systems with different AFOVs or detector materials?; How does the integration of PET and CT data in the uMI Panvivo system specifically improve radiotherapy treatment planning accuracy or interventional radiology guidance workflow compared to using sequential, unlinked PET and CT acquisitions?; What are the performance characteristics (e.g., sensitivity, specificity, nodule detection rates) of the low-dose CT lung cancer screening protocol on the uMI Panvivo, and how do these metrics compare to established national screening trial benchmarks using different CT systems?